Found: 4
Select item for more details and to access through your institution.
MDS-364: STIMULUS MDS-US Trial in Progress: Evaluating Sabatolimab in Combination with Hypomethylating Agents (HMAs) in Patients with Intermediate-, High-, or Very High–Risk Myelodysplastic Syndromes (MDS).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S348, doi. 10.1016/S2152-2650(21)01808-5
- By:
- Publication type:
- Article
Poster: MDS-364: STIMULUS MDS-US Trial in Progress: Evaluating Sabatolimab in Combination with Hypomethylating Agents (HMAs) in Patients with Intermediate-, High-, or Very High–Risk Myelodysplastic Syndromes (MDS).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S230, doi. 10.1016/S2152-2650(21)01452-X
- By:
- Publication type:
- Article
Prevention of Everolimus/Exemestane (EVE/EXE) Stomatitis in Postmenopausal (PM) Women with Hormone Receptor-Positive (HR+) Metastatic Breast Cancer (MBC) Using a Dexamethasone-Based Mouthwash (MW): Results of the SWISH Trial.
- Published in:
- Journal of Oncology Navigation & Survivorship, 2016, v. 7, n. 9, p. 57
- By:
- Publication type:
- Article
Prevention of Everolimus/Exemestane (EVE/EXE) Stomatitis in Postmenopausal (PM) Women with Hormone Receptor-Positive (HR+) Metastatic Breast Cancer (MBC) Using a Dexamethasone-Based Mouthwash (MW): Results of the SWISH Trial.
- Published in:
- Journal of Oncology Navigation & Survivorship, 2016, v. 7, p. 57
- By:
- Publication type:
- Article